<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Urology Product Guide &#187; kidney transplant</title>
	<atom:link href="http://www.urologyproductguide.com/blog/tag/kidney-transplant/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.urologyproductguide.com/blog</link>
	<description>A comprehensive guide to urology products for medical professionals</description>
	<lastBuildDate>Fri, 23 Jul 2010 08:07:11 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Prevention Of Organ Rejection In Stable Kidney Transplant Patients &#8211; LCP-Tacro™ Moves Into Clinical Phase 3</title>
		<link>http://www.urologyproductguide.com/blog/2009/01/02/prevention-of-organ-rejection-in-stable-kidney-transplant-patients-lcp-tacro%e2%84%a2-moves-into-clinical-phase-3/</link>
		<comments>http://www.urologyproductguide.com/blog/2009/01/02/prevention-of-organ-rejection-in-stable-kidney-transplant-patients-lcp-tacro%e2%84%a2-moves-into-clinical-phase-3/#comments</comments>
		<pubDate>Fri, 02 Jan 2009 13:40:27 +0000</pubDate>
		<dc:creator>Seth Sullivan</dc:creator>
				<category><![CDATA[Kidney Disease]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[kidney transplant]]></category>
		<category><![CDATA[LCP-Tacro™]]></category>
		<category><![CDATA[LifeCycle Pharma A/S]]></category>

		<guid isPermaLink="false">http://www.urologyproductguide.com/blog/2009/01/02/prevention-of-organ-rejection-in-stable-kidney-transplant-patients-lcp-tacro%e2%84%a2-moves-into-clinical-phase-3/</guid>
		<description><![CDATA[LifeCycle Pharma A/S has announced the enrollment of the first patient in its Phase 3 clinical trial program for use of LCP-Tacro™ in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the [...]]]></description>
			<content:encoded><![CDATA[<p><img vspace="5" align="left" width="200" src="http://www.urologyproductguide.com/blog/wp-content/uploads/2009/01/lcp.png" hspace="5" height="97" /><a href="http://www.lcpharma.com">LifeCycle Pharma A/S</a> has announced the enrollment of the first patient in its Phase 3 clinical trial program for use of LCP-Tacro™ in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the program. The study will be conducted at approximately 50 sites in U.S. and Europe and the clinical trial results are expected by second half of 2010.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.urologyproductguide.com/blog/2009/01/02/prevention-of-organ-rejection-in-stable-kidney-transplant-patients-lcp-tacro%e2%84%a2-moves-into-clinical-phase-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
